The company's platform integrates RNA bioinformatics, chemical biology tools, and RNA-directed medicinal chemistry to produce a pipeline of small-molecule compounds that act directly on RNA. This approach allows Arrakis to reach hundreds of biological targets not currently accessible to medicine, including known targets previously considered “undruggable.” The company's mission is to impact millions of patients by opening up a new path for discovering RNA-targeted medicines, and they are led by a team of skilled scientists and drug development leaders who are inventive yet pragmatic.